The post Palantir Stock Drops 17% in November Amid AI Valuation Fears and Burry Short appeared on BitcoinEthereumNews.com. Palantir’s stock (PLTR) plunged 17% in November, marking its worst monthly drop since August 2023, driven by valuation fears in AI stocks and a high-profile short position from investor Michael Burry. Investor Pullback: Traders sold AI-linked stocks amid concerns over inflated prices following Michael Burry’s $900 million short on Palantir. Valuation Warnings: Analysts from Jefferies, RBC Capital Markets, and Deutsche Bank highlighted Palantir’s extreme multiples compared to peers like Nvidia. New Deals Amid Decline: Despite the drop, Palantir secured contracts with PwC and FTAI, though they failed to halt the valuation-driven sell-off, with shares at 233 times forward earnings. Discover why Palantir stock plunged 17% in November amid AI valuation fears and Burry’s short. Explore impacts on PLTR and broader market trends—stay informed on stock movements today. What Caused Palantir’s Stock Plunge in November? Palantir stock plunge in November stemmed primarily from investor concerns over elevated valuations in the AI sector, exacerbated by a significant short position disclosed by investor Michael Burry. The stock fell 17%, its steepest monthly decline since August 2023, as traders rotated out of high-priced tech names. Despite strong quarterly earnings, analyst notes questioning the company’s growth sustainability fueled the downturn, leading to a broader retreat in AI-related equities. How Did Analyst Reactions Contribute to the Palantir Stock Decline? Following Palantir’s third-quarter earnings release, which exceeded Wall Street estimates with over $1 billion in revenue for the second consecutive quarter, the mood shifted quickly due to valuation worries. Jefferies issued a note on November 6 describing the valuation as “extreme” and recommended alternatives like Microsoft and Snowflake for better risk-reward profiles. The next day, RBC Capital Markets pointed to an “increasingly concentrated growth profile,” while Deutsche Bank noted the multiples were “very difficult to wrap our heads around.” These critiques, combined with data from Yahoo Finance… The post Palantir Stock Drops 17% in November Amid AI Valuation Fears and Burry Short appeared on BitcoinEthereumNews.com. Palantir’s stock (PLTR) plunged 17% in November, marking its worst monthly drop since August 2023, driven by valuation fears in AI stocks and a high-profile short position from investor Michael Burry. Investor Pullback: Traders sold AI-linked stocks amid concerns over inflated prices following Michael Burry’s $900 million short on Palantir. Valuation Warnings: Analysts from Jefferies, RBC Capital Markets, and Deutsche Bank highlighted Palantir’s extreme multiples compared to peers like Nvidia. New Deals Amid Decline: Despite the drop, Palantir secured contracts with PwC and FTAI, though they failed to halt the valuation-driven sell-off, with shares at 233 times forward earnings. Discover why Palantir stock plunged 17% in November amid AI valuation fears and Burry’s short. Explore impacts on PLTR and broader market trends—stay informed on stock movements today. What Caused Palantir’s Stock Plunge in November? Palantir stock plunge in November stemmed primarily from investor concerns over elevated valuations in the AI sector, exacerbated by a significant short position disclosed by investor Michael Burry. The stock fell 17%, its steepest monthly decline since August 2023, as traders rotated out of high-priced tech names. Despite strong quarterly earnings, analyst notes questioning the company’s growth sustainability fueled the downturn, leading to a broader retreat in AI-related equities. How Did Analyst Reactions Contribute to the Palantir Stock Decline? Following Palantir’s third-quarter earnings release, which exceeded Wall Street estimates with over $1 billion in revenue for the second consecutive quarter, the mood shifted quickly due to valuation worries. Jefferies issued a note on November 6 describing the valuation as “extreme” and recommended alternatives like Microsoft and Snowflake for better risk-reward profiles. The next day, RBC Capital Markets pointed to an “increasingly concentrated growth profile,” while Deutsche Bank noted the multiples were “very difficult to wrap our heads around.” These critiques, combined with data from Yahoo Finance…

Palantir Stock Drops 17% in November Amid AI Valuation Fears and Burry Short

  • Investor Pullback: Traders sold AI-linked stocks amid concerns over inflated prices following Michael Burry’s $900 million short on Palantir.

  • Valuation Warnings: Analysts from Jefferies, RBC Capital Markets, and Deutsche Bank highlighted Palantir’s extreme multiples compared to peers like Nvidia.

  • New Deals Amid Decline: Despite the drop, Palantir secured contracts with PwC and FTAI, though they failed to halt the valuation-driven sell-off, with shares at 233 times forward earnings.

Discover why Palantir stock plunged 17% in November amid AI valuation fears and Burry’s short. Explore impacts on PLTR and broader market trends—stay informed on stock movements today.

What Caused Palantir’s Stock Plunge in November?

Palantir stock plunge in November stemmed primarily from investor concerns over elevated valuations in the AI sector, exacerbated by a significant short position disclosed by investor Michael Burry. The stock fell 17%, its steepest monthly decline since August 2023, as traders rotated out of high-priced tech names. Despite strong quarterly earnings, analyst notes questioning the company’s growth sustainability fueled the downturn, leading to a broader retreat in AI-related equities.

How Did Analyst Reactions Contribute to the Palantir Stock Decline?

Following Palantir’s third-quarter earnings release, which exceeded Wall Street estimates with over $1 billion in revenue for the second consecutive quarter, the mood shifted quickly due to valuation worries. Jefferies issued a note on November 6 describing the valuation as “extreme” and recommended alternatives like Microsoft and Snowflake for better risk-reward profiles. The next day, RBC Capital Markets pointed to an “increasingly concentrated growth profile,” while Deutsche Bank noted the multiples were “very difficult to wrap our heads around.” These critiques, combined with data from Yahoo Finance showing Palantir trading at 233 times forward earnings—far above Nvidia’s 38 times or Alphabet’s 30 times—intensified selling pressure. Expert analysts emphasized that while Palantir demonstrated robust commercial and government sector growth, the premium pricing assumed flawless execution in a competitive AI landscape, a risk heightened by macroeconomic uncertainties.

Frequently Asked Questions

What Impact Did Michael Burry’s Short Position Have on Palantir Stock?

Michael Burry’s disclosure of a $900 million short position on Palantir triggered immediate investor unease, amplifying fears of overvaluation in AI stocks. This move, reported by CNBC, led to a sharp 17% monthly drop as it highlighted potential downside risks, though Palantir’s CEO Alex Karp dismissed it as market manipulation in public appearances.

Why Did Palantir’s Stock Fall Despite Strong Earnings in November?

Palantir reported better-than-expected third-quarter results, including accelerated growth and strong bookings, yet the stock declined due to post-earnings valuation reassessments. Investors worried that the rapid expansion in AI-driven revenue might not justify the lofty multiples, prompting a risk-off approach similar to broader tech sector corrections, as noted in reports from financial outlets like CNBC.

Key Takeaways

  • Valuation as a Key Driver: The Palantir stock plunge underscores how extreme multiples can overshadow positive fundamentals, with shares at 233 times forward earnings signaling high expectations for sustained AI growth.
  • Broader AI Market Impact: The decline mirrored losses in peers like Nvidia (down 12%) and quantum firms like Rigetti (over 33%), reflecting sector-wide concerns over overstretched prices amid economic caution.
  • New Business Momentum: Contracts with PwC for U.K. AI adoption and FTAI for aviation maintenance highlight Palantir’s operational strength—investors should monitor if these offset valuation pressures in future quarters.

Conclusion

The Palantir stock plunge in November, driven by AI valuation fears and high-profile shorts like Michael Burry’s, serves as a cautionary tale for investors in high-growth tech sectors. While the company showcased resilient earnings and strategic partnerships, analyst scrutiny on multiples and growth concentration revealed vulnerabilities in the current market environment. As AI enthusiasm tempers, Palantir’s ability to deliver consistent execution could restore confidence—consider tracking upcoming guidance for signs of stabilization in this dynamic space.

Palantir Technologies, the data analytics firm backed by Peter Thiel, faced a turbulent November as its shares closed the month down 17%, the most severe drop since August 2023, based on data from CNBC. This downturn occurred against a backdrop of investor exodus from AI-associated stocks, spurred by apprehensions over premium pricing. The catalyst was renowned investor Michael Burry’s revelation of a $900 million short bet on the company, which he linked to accusations of hyperscalers inflating AI-related earnings.

In response, Palantir CEO Alex Karp adopted a combative stance during multiple CNBC interviews, labeling Burry’s actions as “egregious” market manipulation. Karp defended the firm’s focus on chips and ontology as essential to its ontology-driven platform, calling shorting it “bats— crazy.” In a shareholder letter, he highlighted how Palantir now democratizes high-return opportunities previously reserved for elite venture capitalists in Silicon Valley.

During the earnings call, Karp’s tone remained unapologetic: “Please turn on the conventional television and see how unhappy those that didn’t invest in us are. Enjoy, get some popcorn. They’re crying. We are every day making this company better, and we’re doing it for this nation, for allied countries.” This defiance came after a promising start to the month, where Palantir surpassed third-quarter revenue and profit forecasts, achieving its second consecutive $1 billion revenue milestone, as covered by Cryptopolitan.

However, the positive results were short-lived. Valuation concerns dominated immediately post-earnings, prompting traders to reduce exposure. Jefferies’ November 6 client note deemed Palantir’s valuation “extreme,” suggesting superior opportunities in other AI players like Microsoft and Snowflake. RBC Capital Markets echoed this on November 7, citing a “concentrated growth profile,” and Deutsche Bank described the pricing as baffling.

Even as the stock weakened, Palantir pursued expansion, announcing a multi-year agreement with PwC to accelerate AI integration in the U.K. and finalizing a deal with FTAI in aircraft engine maintenance. These developments injected vitality into operations but could not stem the tide of valuation-induced selling permeating the AI ecosystem.

The Palantir decline aligned with a sector-wide pullback in overvalued technology stocks. November saw investors offload pricey AI equities amid worries of an overheated market. Nvidia shed more than 12%, while Microsoft and Amazon each declined around 5%. Quantum computing stocks suffered more acutely, with Rigetti Computing and D-Wave Quantum each losing over a third of their value by month’s end. Within the Magnificent 7 group, only Apple and Alphabet posted gains.

Palantir’s shares, despite the rout, still command a premium, trading at approximately 233 times forward earnings according to Yahoo Finance data. This contrasts sharply with Nvidia at 38 times and Alphabet at 30 times as of the latest close, keeping the spotlight on whether current prices fully embed anticipated growth.

Optimism persisted in some quarters. Morgan Stanley upgraded its price target to $205 from $155 on November 4, maintaining an Equal Weight rating, buoyed by nine consecutive quarters of accelerating growth, solid Q4 guidance, and robust Q3 bookings. Conversely, Freedom Capital highlighted longer-term challenges, including potential U.S. commercial slowdown after a banner year, defense budget constraints, and margin pressures from AI-related hiring.

Freedom Capital also cautioned that Palantir’s elevated valuation and growth trajectory are unlikely to endure forever, advising vigilance on execution amid intensifying competition. As the AI narrative evolves, Palantir’s blend of government contracts and commercial AI tools positions it uniquely, yet the November plunge illustrates the volatility tied to high-stakes tech investments. Investors navigating this space should weigh fundamentals against market sentiment for informed decisions.

Source: https://en.coinotag.com/palantir-stock-drops-17-in-november-amid-ai-valuation-fears-and-burry-short

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26